As cancer evolves, so must our tools. The rising challenge of immune-resistant tumors demands therapies that don’t just attack – they retrain the body’s own defenses.

TIMNano is developing a next-generation nano-immunotherapy platform, based on targeted biodegradable nanoparticles that deliver immunomodulators directly to dendridic cells, stimulating both T and B cell responses for long-lasting tumor destruction.

This dual-arm immune strategy offers a cost-efficient, scalable and deeply personalized therapeutic approach – leveraging bioprinted tumors and computer-aided drug design.